Itniv 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis, as well as other systemic and superficial mycoses caused by susceptible fungi. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The capsule formulation ensures optimal bioavailability when taken with food, enhancing absorption. Itniv 200 is typically administered orally once or twice daily, depending on the severity and type of infection. Dosage adjustments may be necessary in patients with hepatic impairment. Common adverse effects include gastrointestinal disturbances, headache, and rash, while serious adverse reactions are rare but may involve hepatotoxicity and cardiac effects such as congestive heart failure. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should be used cautiously with drugs metabolized by the cytochrome P450 system due to potential drug interactions. Regular monitoring of liver function tests is recommended during prolonged therapy. Itniv 200 Capsule should be prescribed and used under medical supervision.